DERM2026 Posters

A 12-Week Phase-IV Evaluation of Safety and Efficacy of Trifarotene Treatment for Facial and Truncal Acne in Indian Subjects Chandrashekar BS, MD; Sushil Tahiliani, MD; Abhishek De, MD; Dyotona Sen, MD NEXT POSTER > POSTER 1

A Narrative Review of Treatment Adherence in Patients With Acne Vulgaris Steven R. Feldman, MD, PhD; Linda Stein Gold, MD; Emil A. Tanghetti, MD; Karol Wroblewski, PharmD; Vivek K. Trivedi, PharmD; Leon H. Kircik, MD < PREVIOUS POSTER NEXT POSTER > POSTER 2

Complete Scalp Hair Regrowth and Predictors of Response in Patients with Alopecia Areata Receiving Ritlecitinib 50 mg up to 3 Years in the ALLEGRO Clinical Trial Program Brett King, Rodney Sinclair, Lidia Rudnicka, Sergio Vañó-Galvan, Bianca Maria Piraccini, Manabu Ohyama, Wenyu Wu, Gianluca Bonfanti, Roger A Edwards, Robert Wolk, Stephen Goodrich, Dalia Wajsbrot, Helen Tran, Alexandre Lejeune < PREVIOUS POSTER NEXT POSTER > POSTER 3

Complete Hair Regrowth in Patients with Alopecia Areata (AA) and ≥25% Scalp Hair Loss Receiving Ritlecitinib up to 3 Years in ALLEGRO-LT Brett King, Rodney Sinclair, Lidia Rudnicka, Sergio Vañó-Galvan, Bianca Maria Piraccini, Manabu Ohyama, Wenyu Wu, Robert Wolk, Stephen Goodrich, Dalia Wajsbrot, Helen Tran, Alexandre Lejeune < PREVIOUS POSTER NEXT POSTER > POSTER 4

Long-Term Efficacy, Complete Scalp Hair Regrowth, and Normal Body Hair and Nails in Patients with Alopecia Areata (AA) Receiving Ritlecitinib 50 mg Once Daily up to 3 Years in the ALLEGRO Clinical Trial Program Brett King, Rodney Sinclair, Lidia Rudnicka, Sergio Vañó-Galvan, Bianca Maria Piraccini, Manabu Ohyama, Wenyu Wu, Robert Wolk, Dalia Wajsbrot, Helen Tran, Alexandre Lejeune < PREVIOUS POSTER NEXT POSTER > POSTER 5